---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sun, Aug 10, 2008 at 11:51 AM
Subject: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
To: mesothelioma77@gmail.com
[1]Semin Oncol. 2008 Jun; 35(3 Suppl 3): S34-43
Bellmunt J, Delgado FM, George C
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
___
Source: http://www.hubmed.org/display.cgi?uids=18538178
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sun, Aug 10, 2008 at 11:51 AM
Subject: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
To: mesothelioma77@gmail.com
[1]Semin Oncol. 2008 Jun; 35(3 Suppl 3): S34-43
Bellmunt J, Delgado FM, George C
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
___
Source: http://www.hubmed.org/display.cgi?uids=18538178
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc